Faculty Member

Donna L. Reynolds M.D., M.Sc., B.Sc.(H)

Email Address(es)
donna.reynolds(at)utoronto.ca
Office Phone
416-447-5531
Office Address
170-5 Fairview Mall Drive Toronto, ON M2J 2Z1
Division(s)/Office
Clinical Public Health Division
Position
Assistant Professor
Appointment Status
Status Only

Research Interests

  • Infectious and non-infectious disease prevention and control
  • Vaccinology
  • Program planning and evaluation
  • Disease and risk factor surveillance
  • Health prioritization
  • Public health methods
  • Surveillance
  • Leadership

Primary Teaching Responsibilities

  • Community Medicine Residents
  • Medical students (Family Medicine Longitudinal Experience)
  • Clerkship medical students

Honours & Awards

  • Ontario Scholar, 1982First Class Honours, Bachelor of Science, Queen’s University, 1986

    Open Fellowship, University of Toronto, 1988-1989

    Licentiate of the Medical Council of Canada, Parts I and II, 1996

    Certificant of the Canadian College of Family Physicians, 1996

    Certificate for Independent Practice, 1996

    Fellow of the Royal College of Physicians of Canada, 1998

    Community Medicine Specialists Certificate, 1998

    Regional Municipality of Durham Award of Excellence for Leadership, 2001

    University of Toronto Field Preceptor Award, 2002

    Regional Municipality of Durham Award of Excellence for Leadership, 2003

    Regional Municipality of Durham Award of Excellence for Leadership, 2004

    Faculty Educator Award, Community Medicine Residency, University of Toronto, 2005

    Distinguished Service Award, Association of Local Public Health Agencies, 2006

    Sanofi pasteur Excellence Effort Energy

    E3 Certificate for Team Spirit, 2006, 2007×2

    Sanofi pasteur Excellence Effort Energy

    Fellow of the Canadian College of Family Physicians, 2008

Current Research Projects

  • Vaccinology
  • Community and Family Medicine

Representative Publications

Kreiger N and Reynolds DL. An investigation of two community-based cancer clusters. Canadian Journal of Public Health 1992; 83: 116-119.

Reynolds DL, Evangelista F, Ward BM, Notenboom RH, Young ER, D’Cunha CO. Syphilis in an urban community. Canadian Journal of Public Health 1998; 89: 248-52.

Muller M, McGeer A, Willey BM, Reynolds D, et al. Outbreak of multi-drug resistant Escherichia coli in long-term care facilities in the Durham, York and Toronto Regions of Ontario, 2000-2002. CCDR 2002; 28(14): 113-118.

Gucciardi E, Pietrusiak M-A, Reynolds D, Rouleau J. Neural tube defects in Ontario, 1986-1999. Canadian Medical Association Journal 2002; 167(3): 237-40.

Johnson IL, Ashley MJ, Reynolds D, Goettler F Lee-Han H, Stratton J, Yim C, Murray J. Prevalence of smoking associated with pregnancy in three southern Ontario health units. Canadian Journal of Public Health 2004; 95(3): 209-213.

Robb M, King SM, Kitai I, Jamieson F, Richardson S, Hellman J, Yaffe B, Reynolds D, Cutz E, Matlow A, And the Outbreak Investigation Team. Nosocomial transmission of congenital tuberculosis in a neonatal intensive care unit. Clinical Infectious Diseases 2004; 39:1719-23.

Reynolds DL, Gillis F, Kitai I, Ennis SL, Silverman M, King SM, Matlow AG, Robb M. Transmission of Mycobacterium tuberculosis from an infant. International Journal of Tuberculosis and Lung Disease 2006; 10(9): 1051-6.

Silverman MS, Reynolds DL, Kavsak P, Garay J, Daly A, Davis I. Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis.Clinical Biochemistry 2007; 40: 913-5.

Reynolds DL, Garay J, Deamond S, Moran K, Devereaux S, Gold W and Styra R. Understanding, compliance and psychological impact of the SARS quarantine experience. Epidemiology and Infection 2008; 136: 997-1007.

Ng W, Reynolds DL, Kennedy E, Feightner K, Holowaty P, Wade K, Fleiszer P, Northrup D and Glascoe F. Measuring the Prevalence of Children at Risk Using Parents’ Evaluation of Developmental Status in a Telephone Survey. Child Indicators Res 2009; Published on-line 23 Oct at: http://www.springerlink.com/openurl.asp?genre=article&id=doi:10.1007/s12187-009-9046-6.

Rabout JM, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, Henry B, Lapinsky S, Loeb M, McDonald C, Ofner M, Paton S, Reynolds D, Scales D, Shen S, Simor AE, Stewart T, Vearncombe M, Zoutman D and Green K. Risk factors for SARS transmission from patients requiring intubation: A multicenter investigation in Toronto, Canada. PLoS ONE 2010; 5(5): e10717.

Grimprel E, Wysocki J, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Immunogenicity and Safety of Fully Liquid DTaP5-IPV-Hib Compared With DTaP3-IPV/Hib When Both Coadministered With a Heptavalent Pneumococcal Conjugate Vaccine (PCV7) at 2, 3, 4, and 12 to 18 Months of Age: A Phase III, Single-blind, Randomized, Controlled, Multicentre Study. Vaccine 2011; 29: 7370-8.

Berner R, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Safety and immunogenicity of fully liquid DTaP5-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP3-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11 to 18 months of age: A phase III, modified double-Blind, randomized, controlled, multicenter study. Vaccine 2012; 30: 5270-7.

Vesikari T, Silfverdal SA, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Immunogenicity and Safety of Fully Liquid DTaP5-IPV-Hib Pediatric Combination Vaccine Compared With DTaP3-IPV/Hib Vaccine Administered at 3, 5, and 12 Months of Age. Clinical and Vaccine Immunology. 2013; 20(10): 1647-53. (Published electronically ahead of print 2013; Aug 21, DOI=10.1128/CVI.00414-13).

Noya F, McCormack D, Reynolds DL, Neame and Oster P. Safety and immunogenicity of 2 doses of quadrivalent meningococcal conjugate vaccine or 1 dose of meningococcal group C conjugate vaccine both administered concomitantly with routine immunization to 12-18 month-old children.” Can J Infect Dis Med Microbiol 2014; 25 (4): 211-6.

Reynolds DL and Vidor E. Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel®): A review of 18 years of clinical experience. Expert Rev Vaccine. 2014; 13(8): 943-68.